Jyoti Mayadev, MD, University of California San Diego Medical Center, San Diego, CA, discusses the rationale, study design, and results of the Phase III CALLA study (NCT03830866). High-risk cervical cancer patients have a risk of recurrence of over 50%, and require more effective treatment options. The prospective, double-blind, placebo-controlled, randomized, global Phase III trial investigated the use of durvalumab with chemoradiotherapy for locally advanced cervical cancer, with the primary endpoint of progression-free survival (PFS). 770 patients were randomized to receive either durvalumab followed by chemoradiotherapy, or a placebo followed by chemoradiotherapy. It was found that there was no difference in PFS rates between patients who received durvalumab compared to those receiving placebo, with 1 year-PFS rates of 76% compared to 73%, and 2 year-PFS rates of 66% compared to 62% respectively. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
